EP1848410A4 - Polymer particle delivery compositions and methods of use - Google Patents

Polymer particle delivery compositions and methods of use

Info

Publication number
EP1848410A4
EP1848410A4 EP06734169A EP06734169A EP1848410A4 EP 1848410 A4 EP1848410 A4 EP 1848410A4 EP 06734169 A EP06734169 A EP 06734169A EP 06734169 A EP06734169 A EP 06734169A EP 1848410 A4 EP1848410 A4 EP 1848410A4
Authority
EP
European Patent Office
Prior art keywords
methods
polymer particle
particle delivery
delivery compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06734169A
Other languages
German (de)
French (fr)
Other versions
EP1848410A1 (en
Inventor
William G Turnell
Hong Li
Zaza D Gomurashvili
Jonathan Macferran Hughes
Jie Da
Huashi Zhang
Ramaz Katsarava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivas LLC
Original Assignee
Medivas LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivas LLC filed Critical Medivas LLC
Publication of EP1848410A1 publication Critical patent/EP1848410A1/en
Publication of EP1848410A4 publication Critical patent/EP1848410A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
    • C08L77/12—Polyester-amides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP06734169A 2005-02-17 2006-01-31 Polymer particle delivery compositions and methods of use Withdrawn EP1848410A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US65471505P 2005-02-17 2005-02-17
US68467005P 2005-05-25 2005-05-25
US68757005P 2005-06-03 2005-06-03
US71995005P 2005-09-22 2005-09-22
US73740105P 2005-11-14 2005-11-14
US75917906P 2006-01-13 2006-01-13
PCT/US2006/003575 WO2006088647A1 (en) 2005-02-17 2006-01-31 Polymer particle delivery compositions and methods of use

Publications (2)

Publication Number Publication Date
EP1848410A1 EP1848410A1 (en) 2007-10-31
EP1848410A4 true EP1848410A4 (en) 2011-11-09

Family

ID=36916776

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06734169A Withdrawn EP1848410A4 (en) 2005-02-17 2006-01-31 Polymer particle delivery compositions and methods of use

Country Status (6)

Country Link
EP (1) EP1848410A4 (en)
JP (1) JP2008530206A (en)
CN (1) CN101115471B (en)
AU (1) AU2006214655A1 (en)
CA (1) CA2596011C (en)
WO (1) WO2006088647A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
CA2623239C (en) 2005-09-22 2016-07-12 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
CA2623198C (en) 2005-09-22 2014-08-05 Medivas, Llc Bis-(a-amino)-diol-diester-containing poly(ester amide) and poly(ester urethane) compositions and methods of use
WO2007112046A2 (en) * 2006-03-24 2007-10-04 Medivas, Llc Alkylene-dicarboxylate-containing biodegradable poly(ester amides) and methods of use
US8658210B2 (en) 2006-04-17 2014-02-25 Advanced Cardiovascular Systems, Inc. Polyesteramide platform for site specific drug delivery
EP2021141A4 (en) * 2006-05-09 2013-07-03 Medivas Llc Biodegradable water soluble polymers
EP2068937A2 (en) * 2006-09-05 2009-06-17 Medivas, LLC Polymer-stabilized liposomal compositions and methods of use
WO2009026543A2 (en) * 2007-08-23 2009-02-26 Medivas, Llc Cationic alpha-amino acid-containing biodegradable polymer gene transfer compositions
US9732142B2 (en) 2008-05-15 2017-08-15 Biocompatibles Uk Limited Intracellular antibody delivery
US20120027859A1 (en) * 2008-10-15 2012-02-02 Turnell William G Biodegradable Proline-Based Polymers
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9963549B2 (en) 2011-06-23 2018-05-08 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
EP3233067B1 (en) 2014-12-18 2019-11-06 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs
WO2016207725A1 (en) * 2015-06-23 2016-12-29 Phagelux (Canada), Inc. Composition comprising amino acid polymers and a bioactive agent and method of preparing thereof
CN110023407B (en) * 2016-09-20 2021-10-29 康奈尔大学 Labeled poly (ester amide urethane), nanoparticles formed therefrom, and uses thereof
CN112321822B (en) * 2020-12-02 2021-12-10 中山大学 Methionine-polyesteramide high-molecular polymer with ROS responsiveness and application thereof
CN114920869B (en) * 2022-05-24 2023-07-14 太原工业学院 Amphiphilic arginine block ciprofloxacin copolymer, nanoparticle, preparation method and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449513A (en) * 1992-08-14 1995-09-12 Research Development Corporation Of Japan Physical trapping type polymeric micelle drug preparation
US5861387A (en) * 1991-06-28 1999-01-19 Endorecherche Inc. Controlled release systems and low dose androgens
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20020015720A1 (en) * 2000-01-11 2002-02-07 Ramaz Katsarava Polymer blends as biodegradable matrices for preparing biocomposites
WO2003062298A1 (en) * 2002-01-17 2003-07-31 Polyrava Llc Co-poly(ester amide) and co-poly(ester urethane) compositions which exhibit biodegradability, methods for making same and uses for same
WO2004039944A2 (en) * 2002-05-15 2004-05-13 Rutgers, The State University Tri-block polymers for nanosphere-based drug or gene delivery
EP1945682A2 (en) * 2005-10-21 2008-07-23 Medivas, LLC Poly(ester urea) polymers and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
CN1281355A (en) * 1997-12-12 2001-01-24 三阳株式会社 Biodegradable mixed polymeric micelles for gene delivery
CA2362263A1 (en) * 1999-02-19 2000-08-24 Bioserv Ag Biodegradable composite material for the production of microcapsules
AU2001230889A1 (en) * 2000-01-11 2001-07-24 Intralytix, Inc. Method and device for sanitation using bacteriophages
CA2397404C (en) * 2000-01-14 2008-12-02 Brown University Research Foundation Micronized freeze-dried particles
FR2811227A1 (en) * 2000-07-07 2002-01-11 Philippe Maincent PARTICULATE VECTORS FOR IMPROVING ORAL ABSORPTION OF ACTIVE PRINCIPLES
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
CN1119172C (en) * 2000-12-12 2003-08-27 天津大学 Chitosan/gelatin network modification on surface of aliphatic polyester
AU2003221497A1 (en) * 2002-03-13 2003-09-22 Novartis Ag Pharmaceutical microparticles
DE60311801T2 (en) * 2002-05-02 2007-11-08 PR Pharmaceuticals, Inc., Fort Collins COMPOSITIONS OF ESTRADIOL METABOLITES WITH CONTROLLED RELEASE
US20090007952A1 (en) * 2004-10-18 2009-01-08 Yoshiomi Kondoh Structure of Peltier Element or Seebeck Element and Its Manufacturing Method

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861387A (en) * 1991-06-28 1999-01-19 Endorecherche Inc. Controlled release systems and low dose androgens
US5449513A (en) * 1992-08-14 1995-09-12 Research Development Corporation Of Japan Physical trapping type polymeric micelle drug preparation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20020015720A1 (en) * 2000-01-11 2002-02-07 Ramaz Katsarava Polymer blends as biodegradable matrices for preparing biocomposites
WO2003062298A1 (en) * 2002-01-17 2003-07-31 Polyrava Llc Co-poly(ester amide) and co-poly(ester urethane) compositions which exhibit biodegradability, methods for making same and uses for same
WO2004039944A2 (en) * 2002-05-15 2004-05-13 Rutgers, The State University Tri-block polymers for nanosphere-based drug or gene delivery
EP1945682A2 (en) * 2005-10-21 2008-07-23 Medivas, LLC Poly(ester urea) polymers and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARABULI N ET AL: "HETEROCHAIN POLYMERS BASED ON NATURAL AMINO ACIDS. SYNTHESIS AND ENZYMATIC HYDROLYSIS OF REGULAR POL(ESTER AMIDE)S BASED ON BIS(L-PHENYLALANINE)ALPHA,OMEGA-ALKYLENE DIESTERS AND ADIPIC ACID", MACROMOLECULAR CHEMISTRY AND PHYSICS, WILEY-VCH VERLAG, WEINHEIM, DE, vol. 195, no. 6, 1 January 1994 (1994-01-01), pages 2279 - 2289, XP002171341, ISSN: 1022-1352, DOI: 10.1002/MACP.1994.021950633 *
See also references of WO2006088647A1 *

Also Published As

Publication number Publication date
AU2006214655A1 (en) 2006-08-24
CN101115471B (en) 2011-02-09
CA2596011C (en) 2013-05-14
EP1848410A1 (en) 2007-10-31
CA2596011A1 (en) 2006-08-24
CN101115471A (en) 2008-01-30
WO2006088647A1 (en) 2006-08-24
JP2008530206A (en) 2008-08-07

Similar Documents

Publication Publication Date Title
EP1848410A4 (en) Polymer particle delivery compositions and methods of use
EP1933881A4 (en) Solid polymer delivery compositions and methods for use thereof
EP1957113A4 (en) Polymer particles for delivery of macromolecules and methods of use
EP2024476A4 (en) Compositions comprising low-dp polymerized surfactants and methods of use thereof
HK1112427A1 (en) Drug delivery compositions and related methods
EP2370455A4 (en) Virus like particle compositions and methods of use
IL195161A0 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
EP2032156A4 (en) Compositions and methods for the delivery of oxygen
EP1973986A4 (en) Bioactive complex compositions and methods of use thereof
ZA200906497B (en) 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
EP2128196A4 (en) Polymer composition and use thereof
GB0911139D0 (en) Directly photodefinable polymer compositions and methods thereof
HRP20160902T1 (en) Compositions and methods of use of phorbolesters
ZA200901386B (en) Masterbatch and polymer composition
IL202684A0 (en) Anti-cd20 therapeutic compositions and methods of use thereof
EP2012803A4 (en) Polymeric compositions and methods of making and using thereof
EP1986685A4 (en) Vaccine delivery compositions and methods of use
EP2152293A4 (en) Compositions for protein delivery and methods of use thereof
EP2233511A4 (en) Novel polymer particle and use thereof
EP2056835A4 (en) Pharmaceutical compositions and uses thereof
EP2064550A4 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
EP1735456A4 (en) Polymeric compositions and related methods of use
EP1966246A4 (en) Methods and compositions for needleless delivery of antibodies
EP2142216A4 (en) Particle formulations and uses thereof
EP1929010A4 (en) Polymer particles and uses thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20111011

RIC1 Information provided on ipc code assigned before grant

Ipc: C08L 75/02 20060101ALI20111005BHEP

Ipc: C08L 75/04 20060101ALI20111005BHEP

Ipc: A61K 9/16 20060101ALI20111005BHEP

Ipc: A61K 47/48 20060101ALI20111005BHEP

Ipc: A61K 9/51 20060101ALI20111005BHEP

Ipc: C08L 75/06 20060101ALI20111005BHEP

Ipc: A61L 31/00 20060101ALI20111005BHEP

Ipc: A61F 2/00 20060101ALI20111005BHEP

Ipc: C12N 15/88 20060101ALI20111005BHEP

Ipc: C08L 77/12 20060101ALI20111005BHEP

Ipc: C07K 16/28 20060101ALI20111005BHEP

Ipc: A61K 9/107 20060101ALI20111005BHEP

Ipc: A61K 47/34 20060101ALI20111005BHEP

Ipc: A61K 9/50 20060101ALI20111005BHEP

Ipc: C08L 77/00 20060101AFI20111005BHEP

Ipc: C08G 18/10 20060101ALI20111005BHEP

Ipc: C08G 69/44 20060101ALI20111005BHEP

17Q First examination report despatched

Effective date: 20121022

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C08L 75/04 20060101ALI20170202BHEP

Ipc: C08G 69/44 20060101ALI20170202BHEP

Ipc: A61K 9/51 20060101ALI20170202BHEP

Ipc: A61K 9/16 20060101ALI20170202BHEP

Ipc: C07K 16/28 20060101ALI20170202BHEP

Ipc: A61K 9/50 20060101ALI20170202BHEP

Ipc: C12N 15/88 20060101ALI20170202BHEP

Ipc: C08G 18/10 20060101ALI20170202BHEP

Ipc: A61F 2/00 20060101ALI20170202BHEP

Ipc: C08L 77/00 20060101AFI20170202BHEP

Ipc: C08L 75/02 20060101ALI20170202BHEP

Ipc: C08L 77/12 20060101ALI20170202BHEP

Ipc: A61L 31/00 20060101ALI20170202BHEP

Ipc: A61K 9/107 20060101ALI20170202BHEP

Ipc: A61K 47/34 20170101ALI20170202BHEP

Ipc: C08L 75/06 20060101ALI20170202BHEP

INTG Intention to grant announced

Effective date: 20170220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170704